El urólogo y las nuevas dianas terapéuticas en el cáncer renal avanzado

Arango Toro, O.

doi:10.1016/S0210-4806(08)73952-4

array:22 ["pii" => "S0210480608739524" "issn" => "02104806" "doi" => "10.1016/S0210-4806(08)73952-4" "estado" => "S300" "fechaPublicacion" => "2008-01-01" "aid" => "73952" "copyright" => "Asociación Española de Urología (AEU)" "copyrightAnyo" => "2008" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2008;32:865-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1030 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 629 "PDF" => 393 ] ] "itemSiguiente" => array:18 [ "pii" => "S0210480608739536" "issn" => "02104806" "doi" => "10.1016/S0210-4806(08)73953-6" "estado" => "S300" "fechaPublicacion" => "2008-01-01" "aid" => "73953" "copyright" => "Asociación Española de Urología (AEU)" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2008;32:868-72" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1144 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 657 "PDF" => 478 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Propuesta para la introducción de temas de historia, arte y literatura en la asignatura urología" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "868" "paginaFinal" => "872" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Proposals for the introduction of history, art and literature issues on the urology subject" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A.M. Tundidor Bermúdez" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A.M." "apellidos" => "Tundidor Bermúdez" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480608739536?idApp=UINPBA00004N" "url" => "/02104806/0000003200000009/v1_201304251914/S0210480608739536/v1_201304251914/es/main.assets" ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "El urólogo y las nuevas dianas terapéuticas en el cáncer renal avanzado" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "865" "paginaFinal" => "867" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "O. Arango Toro" "autores" => array:1 [ 0 => array:4 [ "nombre" => "O." "apellidos" => "Arango Toro" "email" => array:1 [ 0 => "oarango@imas.imim.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">1</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Urología. Hospital del Mar. Barcelona" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "1" "correspondencia" => "Correspondencia autor: Dr. O. Arango Toro Servicio de Urología Hospital del Mar Passeig Maritim, 25-29 - 08003 Barcelona Tel.: 932 483 000" ] ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2008-04-30" "bibliografia" => array:2 [ "titulo" => "Referencias" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:16 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento del carcinoma renal metastático. En: Tratado de Oncología Urológica. Resel L, Moreno J, editores" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Carballido" 1 => "C. Oliver" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Sanidad y Ediciones S.L" "fecha" => "2003" "volumen" => "31" "paginaInicial" => "399" "paginaFinal" => "413" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer statistics, 2006" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "A. Jemal" 1 => "R. Siegel" 2 => "E. Ward" 3 => "T. Murray" 4 => "J. Xu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2006" "volumen" => "56" "paginaInicial" => "106" "paginaFinal" => "130" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16514137" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Capecitabine in the treatment of metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "K. Oevermann" 1 => "J. Buer" 2 => "R. Hoffmann" 3 => "A. Franzke" 4 => "A. Schrader" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1054/bjoc.2000.1340" "Revista" => array:6 [ "tituloSerie" => "Br J Cancer" "fecha" => "2000" "volumen" => "83" "paginaInicial" => "583" "paginaFinal" => "587" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10944596" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Groupe Français d’Immunothérapie. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "S. Negrier" 1 => "F. Gomez" 2 => "J.Y. Douillard" 3 => "A. Ravaud" 4 => "C. Chevreau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00345-004-0467-z" "Revista" => array:6 [ "tituloSerie" => "World J Urol" "fecha" => "2005" "volumen" => "23" "paginaInicial" => "161" "paginaFinal" => "165" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15711829" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunotherapy for metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.F. McDermott" 1 => "B.I. Rini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-410X.2007.06818.x" "Revista" => array:6 [ "tituloSerie" => "BJU Int" "fecha" => "2007" "volumen" => "99" "paginaInicial" => "1282" "paginaFinal" => "1288" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17441925" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "E. Herrmann" 1 => "O.A. Brinkmann" 2 => "M.E. Bode" 3 => "S. Bierer" 4 => "T. Köpke" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2006.11.003" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2007" "volumen" => "51" "paginaInicial" => "1625" "paginaFinal" => "1631" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17113215" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "For The French Immunotherapy Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "S. Negrier" 1 => "D. Perol" 2 => "A. Ravaud" 3 => "C. Chevreau" 4 => "J.O. Bay" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.23056" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2007" "volumen" => "110" "paginaInicial" => "2468" "paginaFinal" => "2477" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17932908" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bevacizumab for patients with metastatic renal cancer: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.C. Yang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/1078-0432.CCR-050006" "Revista" => array:6 [ "tituloSerie" => "Clin Cancer Res" "fecha" => "2004" "volumen" => "10" "paginaInicial" => "6367S" "paginaFinal" => "6370S" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15448032" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "TARGET Study Group. Sorafenib in advanced clear-cell renalcell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "B. Escudier" 1 => "T. Eisen" 2 => "W.M. Stadler" 3 => "C. Szczylik" 4 => "S. Oudard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa060655" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2007" "volumen" => "356" "paginaInicial" => "125" "paginaFinal" => "134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17215530" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Targeted drugs for metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R.J. Motzer" 1 => "E. Basch" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)61874-1" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "370" "paginaInicial" => "2071" "paginaFinal" => "2073" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18156012" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sunitinib versus Interferon alfa in metastatic renalcell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "R.J. Motzer" 1 => "T.E. Hutson" 2 => "P. Tomczac" 3 => "M.D. Michaelson" 4 => "R.M. Bukowski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa065044" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2007" "volumen" => "356" "paginaInicial" => "115" "paginaFinal" => "124" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17215529" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "T.K. Choueiri" 1 => "A. Plantade" 2 => "P. Elson" 3 => "S. Negrier" 4 => "A. Ravaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2007.13.3223" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2008" "volumen" => "26" "paginaInicial" => "127" "paginaFinal" => "131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18165647" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Bellmunt" 1 => "C. Montagut" 2 => "S. Albiol" 3 => "J. Carles" 4 => "P. Maroto" 5 => "A. Orsola" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1464-410X.2006.06589.x" "Revista" => array:6 [ "tituloSerie" => "BJU Int" "fecha" => "2007" "volumen" => "99" "paginaInicial" => "274" "paginaFinal" => "280" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17092282" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Temsirolimus, Interferon alfa, or both for advanced renal-cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "G. Hudes" 1 => "M. Carducci" 2 => "P. Tomczak" 3 => "J. Dutcher" 4 => "R. Figlin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Eng J Med" "fecha" => "2007" "volumen" => "356" "paginaInicial" => "2271" "paginaFinal" => "2281" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Understanding the importante of smart drugs in renal cell carcioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.J. Patard" 1 => "N. Rioux-Leclercq" 2 => "P. Fergelot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2006.01.016" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2006" "volumen" => "49" "paginaInicial" => "633" "paginaFinal" => "643" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16481093" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:5 [ 0 => "N. Bhojani" 1 => "C. Jeldres" 2 => "J.J. Patard" 3 => "P. Perrotte" 4 => "N. Suardi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2007.11.037" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2008" "volumen" => "53" "paginaInicial" => "917" "paginaFinal" => "930" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18054825" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/02104806/0000003200000009/v1_201304251914/S0210480608739524/v1_201304251914/es/main.assets" "Apartado" => array:4 [ "identificador" => "6430" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02104806/0000003200000009/v1_201304251914/S0210480608739524/v1_201304251914/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480608739524?idApp=UINPBA00004N"]

ISSN: 0210-4806

Actas Urológicas Españolas es una revista científica de ámbito internacional dedicada a las enfermedades urológicas y al trasplante renal. Es la publicación oficial de la Asociación Española de Urología desde 1974 y de la Confederación Americana de Urología desde el 2008. Sus artículos abarcan todos los aspectos relacionados con la urología. Actas Urológicas Españolas, que se rige por el sistema de revisión por pares (doble ciego), se publica online tanto en español como en inglés. En consecuencia, los manuscritos pueden ser enviados indistintamente en español o inglés y cuenta con un sistema de traducción bidireccional sin coste adicional para el autor. Su visibilidad y accesibilidad es muy amplia encontrándose presente en: Scientific Citation Index Expanded,, Medline / Pubmed, Embase, JCR, Índice Médico Español, Índice bibliográfico Español en Ciencias de la Salud (IBECS), Cuiden, Dialnet, Hinari, Scopus, Google Scholar.

Ver más Opción Open Access

Revis@r del mes: Dr. Ignacio Pablo Tobia González

Indexada en:

Science Citation Index Expanded, Journal of Citation Reports, Index Medicus/MEDLINE, Scopus, EMBASE/Excerpta Medica, IBECS

Artículo

Opciones para acceder a los textos completos de la publicación Actas Urológicas Españolas

Suscriptor

Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".

Suscribirse a:

Actas Urológicas Españolas

Más información

Comprar

Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora

Contactar

Teléfono para suscripciones e incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España

932 415 960

Llamadas desde fuera de España

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Publique en

Actas Urológicas Españolas

Herramientas

Artículos
recomendados

Seguridad y eficacia del nivolumab para el tratamiento de...

Actas Urol Esp. 2024;48:273-80

Sunitinib versus pazopanib para el tratamiento del...

Actas Urol Esp. 2020;44:27-33

Actas Urológicas Españolas se adhiere a los principios y procedimientos dictados por el Committee on Publication Ethics (COPE)
www.publicationethics.org.

Artículos de acceso gratuito

Vías Clínicas Para El Cuidado Oral En Pacientes...

10.1016/j.acuro.2024.10.004

Recomendaciones de tratamiento en el cáncer de...

Actas Urol Esp. 2024;48:623-31

Impact of COVID-19 outbreak on urology surgical waiting...

Actas Urol Esp. 2021;45:207-14

Revis@r del mes

Dr. Ignacio Pablo Tobia González, revisor del mes de Octubre 2024